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Abstract In this study, cytokine release by tumor-draining 
lymph node cells sensitized in vitro (IVS-TDLN) was 
examined and correlated with therapeutic efficacy in adop- 
tive immunotherapy. Mice bearing immunologically dis- 
tinct MCA 207 and MCA 205 sarcoma tumors were utilized 
in criss-cross experiments. IVS-TDLN obtained from mice 
bearing 10-day subcutaneous (s.c.) rumors mediated im- 
munologically specific regression of established 3-day 
pulmonary metastases, but demonstrated non-specific cyto- 
lytic reactivity against both tumors in a 4-h 5~Cr-release 
assay. By contrast, these IVS-TDLN cells were found 
specifically to secrete granulocyte/macrophage colony- 
stimulating factor (GM-CSF) and interferon Y (IFNy) 
when restimulated in vitro with irradiated tumor cells. To 
determine the predictive value of tumor-specific cytokine 
release with in vivo therapeutic efficacy, a kinetic analysis 
of antitumor activities of TDLN obtained from animals 
bearing MCA 207 tumors for increasing lengths of time was 
performed. IVS-TDLN cells from mice bearing day-7, -10 
and -14 s.c. rumors manifested rumor-specific release of 
GM-CSF and IFNy, and mediated significant antimmor 
reactivity in vivo. In contrast IVS-LN cells from day-0 
and day-21 tumor-bearing animals did not release signifi- 
cant amounts of GM-CSF and IFNy, and were not ther- 
apeutically efficacious in vivo. Day-4 IVS-TDLN released 
high levels of GM-CSF and IFN 7 non-specifically, and 
were not therapeutic in adoptive immunotherapy at doses 
effective for day-7 and day-14 IVS-TDLN cells. In other 
experiments, IVS cells generated from different lymph 
node groups in animals bearing 10-day established s.c. 
tumors were examined and found to have unique profiles 
of cytokine release. In these studies, the ability of IVS cells 
to release specifically both cytokines as opposed to one was 
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associated with greater therapeutic efficacy on a per cell 
basis. Our findings suggest that the tumor-specific releases 
of GM-CSF and IFNy are useful parameters to assess the in 
vivo therapeutic efficacy of immune lymphocytes. 
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Introduction 
One of the difficulties in isolating or generating tumor- 
reactive lymphoid cells for adoptive immunotherapy in man 
has been the availability of reliable in vitro assays that can 
predict in vivo therapeutic efficacy. Unlike animal studies, 
where therapeutic efficacy of immune lymphoid cells can 
be ascertained with in vivo models, characterization of the 
antitumor reactivity of human lymphoid cells has depended 
upon in vitro analyses. Many investigators have utilized in 
vitro tumor lysis as a method to identify potential thera- 
peutic cells. However, there are many examples of non-lyric 
cells capable of mediating tumor regression in adoptive 
immunotherapy [8, 10, 16, 23]. 
More recently, there have been reports suggesting that 
the elaboration of cytokines in tumor-bearing hosts plays a 
significant role in tumor regression. Barth et al. reported 
that the therapeutic efficacy of non-lyric TIL clones in a 
murine model was associated with the ability of these 
clones to secrete interferon y (IFNy) and tumor necrosis 
factor (TNF) in response to tumor in vitro [3]. The role of 
these cytokines as mediators of rumor regression in vivo 
was confirmed by the abrogation of the therapeutic effect of 
tumor-infiltrating lymphocytes (TIL) when neutralizing 
mAb was administered. In this context, TIL appeared to 
be a method to induce local elaboration of these cytokines 
at the sites of rumor, which resulted in tumor regression. In 
other studies, investigators have reported that the elabora- 
tion of various cytokines by genetically modified syngeneic 
tumor cells will result in reduced tumorigenicity and the 
induction of immunity to parental tumor antigens [12]. 
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These observations document a significant role of host 
immuni ty  induced by certain cytokines elaborated in the 
local tumor environment.  In a comparison of several 
different cytokines, Dranoff et al. identified granulocyte/ 
macrophage-colony-stimulating factor (GM-CSF) as one of 
the more potent immunoregulatory peptides, which when 
elaborated in the microenvironment  of the tumor, elicited 
host immuni ty  [7]. 
We have previously reported that tumor-draining lymph 
nodes (TDLN) in animals bearing weakly immunogenic  
tumors harbor lymphoid cells with antitumor reactivity [5, 
6]. These TDLN cells were precursors not capable of 
mediating tumor regression in adoptive immunotherapy, 
and required further in vitro activation in order to differ- 
entiate into functional effector cells. Hence, we have 
referred to TDLN cells as "pre-effector" lymphoid cells. 
One method to activate pre-effector lymphoid cells is to 
stimulate them with irradiated tumor cells in vitro in the 
presence of low concentrations of interleukin-2 (IL-2) [5]. 
In murine models, this in vitro sensitization (IVS) method 
generally required 9 - 1 0  days and resulted in a three- to 
five-fold expansion of tymphoblasts, which were predomi- 
nantly CD8 + T cells. The adoptive transfer of these IVS- 
TDLN cells resulted in the complete regression of estab- 
lished macroscopic tumor associated with long-term sur- 
vival in animal models [6]. Utilizing two immunological ly 
distinct tumors induced chemically from the same murine 
host strain, we investigated the correlation between in vivo 
tumor reactivity and in vitro cytokine release mediated by 
IVS lymphoid cells. We found that the tumor-specific 
release of both GM-CSF and IFN 7 by IVS cells in culture 
was the best determinant of in vivo therapeutic efficacy. 
IL-2 
Human recombinant IL-2 was a gift from Chiron Therapeutics, 
Emeryville, Calif. It has a specific activity of 6 x 106 Cetus units/mg 
protein. One Cetus unit is equivalent to 6 international units (IU). In 
this study, amounts are expressed in international units in all of the 
experiments. 
Tumor-draining lymph node 
B6 mice were inoculated s.c. with 1.5 • 106 MCA 207 or MCA 205 
tumor cells in the lower flank. At specific intervals after tumor 
inoculation the adjacent tumor-draining inguinal lymph nodes were 
harvested, and single-cell suspensions prepared mechanically as de- 
scribed previously [23]. In other studies, axillary and mesenteric lymph 
nodes were similarly prepared for comparison with inguinal nodes. 
Axillary and mesenteric nodes represent further removed nodal sites 
compared with inguinal nodes in relation to lower-flank tumors. 
Single-cell suspensions were cultured by the IVS procedure. 
IVS procedure 
The procedure for generating IVS lymphoid cells has been previously 
described [6]. Briefly, 4 x 105 responding lymph node cells and 4 x 105 
irradiated (60 Gy) MCA 207 or MCA 205 tumor stimulator cells were 
cultured in 2.0 ml complete medium (CM) containing 60 units/ml IL-2 
in 24-well tissue-culture plates (Costar, Cambridge, Mass.). CM con- 
sisted of RPMI-1640 medium supplemented with 10% heat-inactivated 
fetal calf serum, 0.01 mM non-essential amino acids, 1 ~tM sodium 
pyruvate, 2 mM fresh L-glutamine, 100 gg/ml streptomycin, 100 g/ml 
penicillin, 50 gg/ml gentamycin, and 0.5 gg/ml fungizone (all reagents 
from Gibco). The cultures were incubated at 37 ~ in 5% CO2 and 
were fed with 1.0 ml CM containing 60 IU/ml IL-2 on days 5 and 7. 
The IVS cells were routinely harvested on day 9 when they grew to a 
high density. These cells were washed three times before being 
resuspended in Hanks' balanced salt solution (HBSS) for adoptive 
immunotherapy or in CM for cytotoxicity and cytokine release. 
Materials and methods 
Mice 
Female C57BL6 (B6) mice were purchased from The Jackson Labo- 
ratory (Bar Harbor, Me.) and maintained in a specific-pathogen-free 
environment. They were used at the age of 8 weeks or older. Principles 
of laboratory animal care (NIH publication 85-23, revised 1985) were 
followed, and animal protocols approved by the University of Michi- 
gan Laboratory of Animal Medicine. 
Tumor 
The MCA 207 and MCA 205 are 3-methylcholanthrene-induced 
fibrosarcomas, syngeneic to B6 mice. These tumors have been main- 
tained in vivo by serial subcutaneous (s.c.) transplantation in B6 mice 
and were used within the seventh transplantation generation. They 
were kindly provided by Dr. James C. Yang (National Cancer Institute, 
NIH, Bethesda, Md.). These tumors have been previously characterized 
to be weakly immunogenic with distinct tumor-specific transplanta- 
tion-rejection antigens [2]. Routinely, tumor cell suspensions were 
prepared from solid tumors by enzymatic digestion in 40 ml Hank's 
balanced salt solution (HBSS) [Grand Island Biological Co. (Gibco), 
Grand Island, N. Y.] containing 40 mg collagenase, 4 mg DNase and 
100 units hyaluronidase (all obtained from Sigma Chemical Co., St. 
Louis, Mo.) for 3 h at room temperature as previously described [23]. 
Generation of LAK cells 
Lymphokine-activated killer (LAK) cells were generated by in vitro 
culture with high concentrations of IL-2. Briefly, l0 s normal B6 
splenocytes were placed into 150-cm 2 (750 ml) flasks in 50 ml CM 
with 6000 IU/ml IL-2. The flasks were incubated at 37 ~ 5% CO2 for 
72 h. The LAK cells were then harvested in sterile centrifugation tubes 
and washed three times in HBSS before resuspension in HBSS for i. v. 
injection or in CM for in vitro assays. 
Adoptive immunotherapy 
B6 mice were inoculated i.v. with 2 x 105-2.5 • 105 MCA 207 or 205 
tumor cells to establish pulmonary metastases. Three days after tumor 
inoculation, mice were infused i.v. with IVS cells and given i.p. 
injections of IL-2 (60000 IU) continuing twice daily for 4 days, 
commencing on the day of cell transfer. Approximately 3 weeks 
after tumor initiation, mice were randomized and sacrificed for 
enumeration of pulmonary nodules. The metastases appeared as dis- 
crete white nodules on the black surface of lungs insufflated with a 
15% solution of India ink and bleached by Fekette's solution [23]. 
Metastatic foci too numerous to count were assigned an arbitrary value 
of > 250. The significance of differences in numbers of metastatic 
nodules between experimental groups was determined using the non- 
parametric Wilcoxon rank-sum test. Two-sided P valanes below 0.05 
were considered significant. Each group consisted of at least five mice, 
and no animal was excluded from the statistical evaluation. 
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Table 1 Specificity of tumor regression mediated by in-vitro-sensi- 
tized tumor-draining lymph node (IVS-TDLN') cells in adoptive im- 
munotherapy. Ten days after MCA 205 or MCA 207 tumor s.c. 
inoculation, TDLN were harvested for IVS culture. Samples containing 
4 x 105 TDLN cells were cultured with 4 x 105 irradiated tumor cells in 
the presence of IL-2 (60 IU/ml) for 9 days. Mice were inoculated with 
2 x 105 MCA 205 or MCA 207 tumor cells i.v. Three days later, mice 
received tVS-TDLN cells i. v. along with a concomitant administration 
of IL-2 (60000 IU) i.p. twice daily for a total of eight doses. Lungs 
were harvested on day 19. IL-2 interleukin-2 
IVS effector cells* Adoptive immunotherapy 
No of cells IL-2 Mean no. pulmonary 
transferred metastases (SEM) 
MCA 207 MCA 205 
- - > 250 > 250 
- + > 250 > 250 
MCA 207 TDLN 1.2 x 107 + 0* 225 (8) 
MCA 205 TDLN 1.2 • 107 + 238 (12) 10 (4)* 
* P <0.01 compared to other groups 
Immunofluorescent staining and flow cytometry 
Table 2 Cytolytic activity of TDLN after IVS. The effector cells were 
the IVS-TDLN cells generated for the experiment described in Table 1. 
Lymphokine-activated killer (LAK) cells were established from normal 
splenocytes incubated in 6000 IU/ml IL-2, and were used as positive 
controls for tumor lysis. Fresh tumor cells were utilized as targets in a 
4-h 51Cr-release assay. Results show the percentage lysis assessed at 
various effector:target ratios 
Lysis (%) 
Effector cells Target 100:1 20 : 1 4:1 0.8 : 1 
MCA 207 TDLN MCA 207 22 20 16 2 
MCA 205 15 13 II 6 
MCA 205 TDLN MCA 207 30 18 9 8 
MCA 205 40 25 23 15 
LAK MCA 207 38 29 19 9 
MCA 205 33 28 12 0 
performed. For IFNu TNF~ and IL-4; standard curves starting at 
1000 IU/ml, 50 ng/ml, and 1000 IU/ml respectively were established in 
a similar fashion. Experimental values were computed with the use of 
regression analysis. 
Analysis of cell-surface phenotypes of IVS cells was carried out by 
indirect immunofiuorescent staining. Briefly, (5 - 10) • 105 cells were 
incubated for 45 min at 4 ~ with 25 gl appropriately diluted mAb in 
phosphate-buffered saline containing 2% fetal bovine serum and 0.1% 
NAN3. Rat mAb against the murine CD4 (GKI.5, L3T4) and CD8 
(2.43, Lyt-2.2) were used in ascites form phenotyping of murine T cells 
(obtained from the American Type Culture Collection, Rockville, 
Md.). A rat mAb specific for the murine IL-2 receptor (IL-2R) 
(7D4) was used a primary antibody for the detection of the expression 
of IL-2R. Bound antibodies were detected by incubation with 20 gl of 
the fluorescein-isothiocyanate-labeled mAb to rat ~: chain (MAR 18.5, 
PharMingen, San Diego, Calif.). Stained cell preparations were ana- 
lyzed in a FACScan flow microfluorometer (Becton Dickinson, Sun- 
nyvale, Calif.). Fluorescence profiles were generated by analyzing 
10000 cells and displayed as logarithmically increasing fluorescence 
intensity versus cell numbers. 
Cytotoxicity assay 
A standard 4-h slCr-release assay was used to assess the cytotoxic 
reactivity of IVS cells. Briefly, (5 - 10) x 106 tumor target cells were 
labeled with slCr (Na51CrO4; 50 mCi; New England Nuclear, Boston, 
Mass.) for 1 h. Labeled target cells (104) were incubated with various 
numbers of effector cells in 0.2 ml CM in plates containing 96 U- 
bottomed wells and incubated at 37 ~ for 4 h. After incubation, the 
supernatants were collected by the Titertek collecting system (Flow 
Laboratories, McLean, Va.) for gamma counting. The percentage lysis 
was calculated as [(experimental slCr release - spontaneous release)/ 
(maximal release - spontaneous release)] x 100. 
Measurement of in vitro cytokine release by IVS cells 
Release of GM-CSF, IFN 7, TNF0~ and IL-4 by IVS lymphoid cells in 
response to tumor cell stimulation was assessed. IVS cells (1 x 106/ml) 
and irradiated tumor cells (5 x 105/ml) were co-cultured in 2.0-ml 
volumes in 24-well tissue-culture plates. Tumor cells were irradiated 
with 6000 cGy by a 137Cs source (500 cGy/min, Gamma Cell 1000 
Irradiator, Atomic Energy of Canada). After 24 h, culture supernatants 
were collected and cytokine measurements assessed in duplicate using 
commercially available enzyme-linked immunosorbent assays 
(ELISA) (Pharmingen, San Diego, Calif.). For murine GM-CSF, a 
standard curve starting at 12.5 ng/ml with serial twofold dilutions was 
Results 
In v ivo  tumor  speci f ic i ty  of  I V S - T D L N  cells  did not  
corre la te  wi th  in vi t ro  cy to ly t ic  reac t iv i ty  
The  speci f ic i ty  o f  tumor  regress ion  media ted  by I V S - T D L N  
was assessed by the adopt ive  i m m u n o t h e r a p y  of  two 
i m m u n o l o g i c a l l y  dist inct  tumors  in a cr iss-cross  exper i -  
ment.  T D L N  harves ted  10 days after the s.c.  inocula t ion  o f  
1.5 x 106 M C A  205 or  M C A  207 tumor  cells  were  cul tured  
by the IVS method.  Af te r  IVS culture,  1.2 x 107 IVS cel ls  
were  adopt ive ly  t ransferred to m i c e  bear ing  3-day puhno-  
nary tumors  a long  with  the concomi t an t  i .p .  adminis t ra t ion  
o f  60 000 IU  IL-2  twice  dai ly  for  e ight  doses.  As  summa-  
r ized in Table 1, IL-2  adminis t ra t ion  a lone  did not  result  in 
tumor  regression.  H o w e v e r ,  the t ransfer  o f  I V S - T D L N  cells 
plus IL-2  media ted  i m m u n o l o g i c a l l y  speci f ic  tumor  regres-  
sion. 
The  phenotyp ic  character is t ic  o f  T D L N  cells were  
de te rmined  before  and after IVS cul ture  by f luorescence-  
ac t iva ted  cel l  sorting. Fresh T D L N  compr i sed  approx imate -  
ly 3 0 % - 4 0 %  T h y l . 2  + T cel ls  wi th  an approx imate ly  2 : 1  
ratio o f  C D 4  : CD8-pos i t i ve  cells. Af te r  IVS culture,  the cel l  
popula t ion  was at least  90% T h y l . 2  + cel ls  witlq~ vir tual ly  all 
the cel ls  bear ing  CDS.  
The  in vi tro cy to ly t ic  reac t iv i ty  o f  the cells ana lyzed  in 
adopt ive  i m m u n o t h e r a p y  (Table 1) was also eva lua ted  us ing 
a 4-h  51Cr-release assay. Both  I V S - T D L N  popula t ions  
med ia t ed  lyt ic  reac t iv i ty  against  the tumor  with which  
they were  p r imed  in v ivo  (Table 2). H o w e v e r ,  there was  
s igni f icant  lysis o f  the unre la ted  tumor  as well ,  a lbei t  at a 
l ower  level .  L A K  cells  genera ted  f rom normal  sp lenocytes  
by incubat ing  in 6000 I U / m l  IL-2  med ia t ed  non-spec i f i c  
lysis of  both  tumor  targets as expected .  The  speci f ic i ty  o f  in 
v ivo  tumor  regress ion  med ia ted  by I V S - T D L N  was not  
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Table 3 Tumor-specific cytokine release before and after IVS culture. 
TDLN cells were harvested from mice inoculated with M C A  205 or 
MCA 207 tumor cells as described in Table 1. IVS cultures were 
established as described in Table 1. Cytokine release was measured 
from the culture supernatant of  TDLN cells restimulated with irra- 
diated tumor cells for 24 h. Values reflect the amount  of  released 
cytokine after subtraction of low background amounts  measured from 
irradiated tumor cells and TDLN ceils alone. IFNy interferon y. GM- 
CSF granulocyte/macrophage-colony-st imulat ing factor 
TDLN cells 
Cytokine release 
IFNy (IU/ml) GM-CSF (pg/ml) 
IVS MCA 207 MCA 205 MCA 207 MCA 205 
MCA 207 Before 0 0 0 0 
After 76 0 780 0 
MCA 205 Before 0 0 0 0 
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Table 4 Kinetics of  in vivo efficacy of M C A  207 TDLN after IVS. 
Mice were inoculated s.c. with M C A  207 tumor cells. At  different 
intervals after tumor inoculation, inguinal T DL N were harvested for 
IVS culture as described in Table 1. The tumor reactivity of  the IVS- 
TDLN cells was assessed in the adoptive immunotherapy of 3-day 
established M C A  207 pulmonary metastases as described in Table 1 
Days after s.c. tumor IL-2 
inoculation 
Adoptive immunotherapy: 
mean no. of pulmonary 
metastases (SEM) 
- - > 250 
- + > 250 
0 + > 250 
4 + 241 (7) 
7 + 6 (4)* 
10 + 5 (4)* 
14 + 29 (22)* 
21 + 176 (53)** 
* P <0.01 compared to all other groups 
** P <0.01 compared to groups with more than 250 mean pulmonary 
metastases 
reflected by the tumor specificity of in vitro lysis. Of 
interest, LAK therapy at comparable cell doses was not 
effective in mediating tumor regression either (see later). 
In vitro cytokine release by IVS-TDLN cells 
We proceeded to examine the release of cytokines by 
TDLN cells as a means to assess in vitro immunological 
reactivity. TDLN were harvested 10 days after MCA 205 or 
MCA 207 tumor inoculation and cultured by the IVS 
method. TDLN cells before and after IVS were assessed 
for cytokine release by culturing these cells with irradiated 
MCA 205 or MCA 207 tumor cells for 24 h. The culture 
supernatants were harvested and assayed for IFNy, GM- 
CSF, IL-4 and TNFo~ Freshly harvested TDLN cells did not 
secrete cytokines after tumor stimulation (Table 3). How- 
ever, after IVS culture, MCA 207 IVS-TDLN cells demon- 
strated specific GM-CSF and IFNy release when restimu- 
lated by MCA 207, and not with MCA 205. By contrast, 
Fig. 1 Kinetics of granulocyte/macrophage-colony-stimulating factor 
(GM-CSF) secretion from in-vitro-stimulated tumor-draining lymph 
node (IVS-TDLN) cells obtained from mice bearing MCA 207 tumors 
for different lengths of time. Culture supernatants were collected 24 h 
after restimulation with irradiated MCA 207 or MCA 205 tumor cells. 
Values reflect the amount of released cytokine after subtraction of 
amounts measured from tumor cell alone 
MCA 205 IVS-TDLN cells released GM-CSF and IFNy 
when restimulated with MCA 205, but not MCA 207. IVS- 
TDLN cells did not release deflectable IL-4 or TNFcz after 
tumor restimulation. 
We next examined the kinetics of pre-effector cell 
development in TDLN. MCA 207 tumor cells were inocu- 
lated s.c. and TDLN harvested every few days for cryo- 
preservation up to day 21 after tumor inoculation. Upon 
collecting all the TDLN from the different interval times, 
the cells were thawed, washed, and cultured by the IVS 
method. After IVS culture, these IVS-TDLN cells were 
assessed for therapeutic efficacy by adoptive transfer 
(1.2 x 107 cells/animal) into mice with established 3-day 
MCA 207 pulmonary metastases (Table 4). TDLN har- 
vested on days 0 and 4 had no therapeutic reactivity 
compared to control groups. IVS cells generated from 
TDLN harvested on days 7, 10 and 14 after tumor inocula- 
tion mediated significant regression of pulmonary metasta- 
ses. By day 21, there was diminished pre-effector cell 
activity in the TDLN. 
In kinetic studies, we also evaluated the tumor-specific 
cytokine release of the IVS-TDLN cells. After culture in 
IVS, TDLN cells were restimulated in vitro with irradiated 
MCA 207 or MCA 205 tumor and the supernatant was 
harvested 24 h later for cytokine (GM-CSF and IFNy) 
determinations (Fig. 1, 2). There were no significant 
amounts of GM-CSF or IFN 7 released by day-0 IVS- 
TDLN. Day-4 IVS-TDLN cells secreted high amounts of 
both cytokines non-specifically. Tumor-specific cytokine 
release was observed in TDLN harvested up to 14 days 
after tumor inoculation and diminished by day 21 to levels 
similar to those of day-0 TDLN (i. e., normal lymph nodes). 
These results suggested that a correlation existed between 
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Table 6 Minimal  in vivo therapeutic efficacy of murine LAK in the 
therapy of MCA 207 pulmonary metastases. LAK cells were generated 
as described in Table 5. The tumor reactivity of LAK cells was 
assessed in the adoptive immunotherapy of 3-day established 
MCA 207 pulmonary metastases as described in Table 1 
No. of IL-2 Mean 
LAK 
no. of pulmonary metastases (SEM) 
Expt. 1 Expt. 2 
- - > 2 5 0  > 2 5 0  
- + > 2 5 0  > 2 5 0  
0.6 x 107 + > 2 5 0  
1.2 x 107 + 249 (1) - 
2.4 x 107 + 245 (5) - 
4.8 x 107 + 203 (7) 240 (9) 
10.0 • 107 + 54 (15)* 
* P <0.01 compared to all other groups 
Fig. 2 Kinetics of IFNy secretion from IVS-TDLN cell obtained from 
mice bearing MCA 207 tumors for different lengths of time. Culture 
supernatants were collected as described in Fig. 1. There was negli- 
gible IFNy secretion from tumor cells alone 
vivo therapeutic efficacy of IVS-TDLN cells. In addition, it 
was evident that host- or tumor-related factors appeared to 
play a role in down-regulating the activity of pre-effector 
TDLN cells during the course of progressive tumor growth. 
LAK phenomenon 
reduced the number of pulmonary metastases, LAK cells 
were ineffective. Only at much greater numbers of LAK 
cells (i. e., 108) was antitumor reactivity identified. These 
numbers are consistent with the antitumor efficacy of LAK 
cells in previous reports [15, 21]. These observations 
suggested that the non-specific release of cytokines by 
effector cells in response to tumor stimulation is not as 
predictive as tumor-specific release in determining their 
therapeutic potential in vivo. Nevertheless, at sufficiently 
high numbers of transferred cells, LAK-like cells can 
mediate tumor regression. 
The non-specific release of cytokines demonstrated by day- 
4 TDLN was suggestive of a LAK-like phenomenon. 
Therefore, we proceeded to examine the cytokine-release 
profile and therapeutic efficacy of standard LAK cells in 
our models. The in vitro cytokine release mediated by LAK 
cells generated from normal splenocytes was evaluated. As 
demonstrated by in vitro cytotoxicity assays, LAK cells 
were found to lyse MCA 205 and MCA 207 in a non- 
specific manner (Table 2). In both of two experiments, LAK 
cells were also found to release GM-CSF and IFNy non- 
specifically when stimulated by irradiated MCA 205 and 
MCA 207 tumor in vitro (Table 5). 
The therapeutic efficacy of LAK cells was examined in a 
dose-escalation fashion in the treatment of 3-day estab- 
lished MCA 207 pulmonary metastases (Table 6). At a dose 
of IVS-TDLN cells (i.e., 1.2 x 107) that significantly 
Table 5 Non-specific cytokine release of LAK cells. LAK cells were 
generated from splenocytes incubated in 6000 IU/ml IL-2 for 3 days. 
Cytokine release was measured in culture supernatants as described in 
Table 4. LAK cells cultured in the absence of tumor cells did not 
secrete either cytokine 
Cytokine release 
IFN~(IU/ml) GM-CSF (pg/ml) 
Experiment MCA 207 MCA 205 MCA 207 MCA 205 
i 103 228 478 416 
2 204 128 495 297 
Distribution of pre-effector cells in different lymph nodes 
The regional draining lymph node has been known to be a 
critical lymphoid organ during the immunological response 
to antigenic stimulation [19, 22]. We have previously 
demonstrated that the distribution of tumor-reactive pre- 
effector cells can vary, depending upon the source of 
lymphoid ceils in the tumor-bearing host. We proceeded 
to investigate the correlation between tumor-specific cyto- 
kine release of IVS cells obtained from different lymph 
node sites of MCA 207 tumor-bearing hosts and their in 
vivo therapeutic efficacy. B6 mice were inoculated in the 
lower flank with MCA 207 tumor cells and 10 days later 
had inguinal, axillary and mesenteric lymph nodes removed 
for IVS culture. Normal splenocytes were used as control 
cells. After IVS culture, cells were assessed for in vitro 
cytokine release after tumor restimulation or in vivo tumor 
reactivity by the adoptive immunotherapy of pulmonary 
metastases as previously described. In order to quantify 
tumor-specific cytokine release, a specific release ratio 
(SRR) was calculated: 
SRR = 
total cytokine release against specific tumor tumor alone effectur cells alone 
total cytokine release against non specific tumor tumor alone effector cells alone 
As summarized in Table 7, tumor regression was 
mediated by all three IVS-LN populations at the highest 
cell dose transferred (1.2 x 107). However, dose titration 
revealed that the therapeutic potency of each cell popula- 
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Table 7 Correlation between in vitro tumor-specific cytokine release 
and in vivo efficacy of different IVS-LN cells from MCA 207 tumor- 
bearers. Mice were inoculated s.c. with MCA 207 tumor cells in the 
lower flank and underwent removal of lymph nodes (LN) 10 days later 
for IVS culture as described in Table 1. Cytolytic activity (lyric units, 
LU) was determined by 20% lysis of l04 target cells in 106 effector 
cells. Mice were inoculated with MCA 207 tumor cells i.v. to establish 
pulmonary metastases; 3 days later, IVS-LN cells were adoptively 
transferred i.v. with the concomitant administration of IL-2 as de- 
scribed in Table 1. The percentage reduction of metastases was 
calculated for each IVS-LN cell dose with respect to control animals 
that received IL-2 alone. SRR specific release ratio of cytokine 
Source of SRR Cytolytic activity (LU) 
IVS LN cells GM-CSF IFN7 MCA 207 MCA 205 
Reduction of metastases (%) 
1.2 x 10 6 6 x 10 6 3 x 10 6 1.5 x 10 6 
Inguinal LN 17.2 29 9 9.5 
Axillary LN 1.3 40 9.5 13.7 
Mesenteric LN < 1 64 1.9 62.1 
Normal spleen < 1 3 < 1 82 
100" 88* 31" 18 
98* 23 5 0 
80* 2 0 0 
0 - -  - -  - -  
* P <0.01 compared to control animals that received IL-2 alone 
tion varied, the inguinal IVS-LN cells being the most 
effective followed by the axillary and mesenteric IVS-LN 
cells in decreasing order. Normal IVS cultured splenocytes 
had no therapeutic activity at the highest cell dose, and 
were found to have negligible tumor-specific release of 
GM-CSF and IFN 7. Tumor-specific release of both cyto- 
kines appeared to be associated with the greatest in vivo 
therapeutic efficacy as observed with inguinal IVS-LN 
cells. High tumor-specific release of IFN 7 with minimal 
tumor-specific release of GM-CSF was associated with low 
to intermediate reduction of pulmonary metastases, as 
observed with axillary and mesenteric IVS-LN cells. 
Discussion 
One of the major obstacles confronting investigators in the 
generation of tumor-reactive lymphocytes for adoptive 
immunotherapy is the unavailability of reliable in vitro 
assay methods to identify therapeutically functional effector 
cells. We and others have demonstrated that the use of 
standard 4-h chromium-release assays is not predictive of 
whether a particular cell population can mediate tumor 
regression in vivo [8, 10, 16, 23]. More recently, several 
reports have indicated that cytokine secretion by TIL 
appears to correlate with the in vivo tumor regression 
mediated by those cells. Barth et al. isolated several murine 
TIL clones from various methylcholanthrene(MCA)-in- 
duced tumors which were CD8 + and non-cytolytic [3]. He 
was able to demonstrate that the secretion of IFN 7 and 
TNFc~ upon restimulation of these TIL clones was asso- 
ciated with their antitumor reactivity in vivo. Moreover, the 
therapeutic efficacy of the cells was attenuated by neutral- 
izing monoclonal antibodies to these cytokines. Goedege- 
buure et al. demonstrated that the release of IFN 7 and GM- 
CSF by TIL during activation and expansion with anti-CD3 
and IL-2 appeared to correlate with their in vivo antitumor 
reactivity in the MCA 105 tumor model [9]. TIL isolated 
from different culture conditions were non-specifically lytic 
to various tumor targets in their study. They found that the 
elaboration of GM-CSF and IFN- 7 by TIL during culture 
was associated with the magnitude of tumor regression 
manifested by the TIL after adoptive transfer. There have 
been few clinical studies of adoptive immunotherapy to 
determine whether one can extrapolate these observations 
to humans. In one of the largest clinical experiences with 
TIL therapy at the National Cancer Institute, Schwartzen- 
truber et al. reported that the release of GM-CSF by TIL in 
response to autologous tumor appeared to be an important 
independent predictor of tumor response in melanoma 
patients [ 18]. 
We have further investigated the association of cytokine 
release by effector T cells and their therapeutic efficacy in 
vivo. Rather than utilizing TIL, we examined the in vitro 
reactivity of TDLN secondarily stimulated by tumor in an 
IVS culture method we have previously described [5, 6]. To 
evaluate tumor specificity we employed two immunologi- 
cally distinct MCA-induced sarcomas that were derived in 
the same mouse strain. Tumor regression mediated by IVS- 
TDLN was exquisitely specific; however, the cytolytic 
reactivity was not. By contrast, the release of GM~CSF 
and IFN 7 by competent IVS-TDLN was highly tumor- 
specific. 
We also observed that the ability to secrete GM-CSF or 
IFN7 in a non-specific manner was not as predictive as the 
specific release of these cytokines for the mediation of 
tumor regression in vivo. For example, LAK cells were 
found to elaborate high levels of GM-CSF and IFN 7 in a 
non-specific manner in vitro. Yet on a per cell basis, LAK 
cells were not as potent as IVS-TDLN cells that secreted 
cytokines in a tumor-specific fashion. Moreover, we found 
that day-4 IVS-TDLN secreted high amounts of GM-CSF 
and IFNy non-specifically and were therapeutically ineffec- 
tive compared to day-7-14 IVS-TDLN, which released 
these cytokines in a tumor-specific manner. As a corollary, 
cells that did not secrete significant amounts of GM-CSF or 
IFN7 in response to in vitro tumor stimulation (i. e., normal 
splenocytes or day-21 TDLN) had no efficacy in adoptive 
immunotherapy. 
The ability of effector cells to secrete both cytokines in a 
specific fashion appeared to be better than their release of a 
single cytokine. As noted in Table 7, the tumor-specific 
release of IFN7 was demonstrated by IVS-cultured LN cells 
from inguinal, axillary and mesenteric node groups. At a 
relatively high dose of adoptively transferred cells (i. e., 
1.2 • 107), tumor regression was mediated by all three cell 
populations. However, only inguinal lymph node cells that 
were derived from the closest nodal group draining the 
tumor inoculum demonstrated the specific release of  both 
cytokines, and also had the most potent therapeutic effect in 
vivo on a per cell basis. 
Both GM-CSF and IFNy have been found to be impor- 
tant cytokines in the host response to progressive tumors. 
Utilizing gene-transfer techniques several investigators 
have demonstrated that the elaboration of  GM-CSF and 
IFNs' by genetically modified tumors will enhance T cell 
sensitization of  the host. Using a poorly immunogenic 
tumor, Dranoff  et al. reported that GM-CSF elaboration 
by the B16 melanoma was successful in establishing 
systemic immunity to wild-type tumor in a naive host [7]. 
Our laboratory, utilizing a subline of  the B16 tumor, B16- 
BL6, demonstrated the ability to induce antitumor-reactive 
cells in lymph nodes draining a clone of  the B16-BL6 
engineered to secrete GM-CSE in contrast to wild-type 
tumor, which did not [1]. The antitumor reactivity of  the 
lymph node cells was assessed in adoptive immunotherapy 
experiments. The role of  GM-CSF in these models appears 
to be related to an increased influx of  antigen-presenting 
cells to the local tumor environment as well as the draining 
lymph nodes. Other investigators have demonstrated the 
activation of  dendritic cells by GM-CSF, which may also be 
important in antigen processing and presentation [4, 13, 
17]. By similar mechanisms, the ability of  adoptively 
transferred mature effector cells to elaborate GM-CSF in 
response to autologous tumor may be important in the 
recruitment of  hot cells to respond at the site of progressive 
tumor. 
The interferons have been postulated to have a variety of  
immunomodulatory effects important in tumor immunity. 
These include macrophage activation, naturall killer cell 
activation, and up-regulation of  tumor antigens and MHC 
molecules [11]. Another novel role IFN 7 may serve is to 
induce tumor cells to become "non-professional" antigen- 
presenting cells. Restifo et al. observed that MCA 101, a 
poorly immunogenic murine sarcoma, developed the capa- 
bility of  processing exogenous antigen by genetically mod- 
ifying a tumor line with IFN7 cDNA [14]. This was 
associated with up-regulation of  tumor immunogenicity 
since TIL derived from IFNT-transduced MCA 101 were 
therapeutically effective compared to TIL generated from 
the wild-type tumor. The release of  IFN 7 by adoptively 
transferred effector T cells may promote tumor regression 
via similar mechanisms. 
We are currently evaluating the predictive effect of  
tumor-specific cytokine release with the functional in 
vivo antitumor activity of  other effector populations. 
These include TDLN cells activated by anti-CD3 [23], 
and bacterial superantigens [20]. These studies will also 
allow us to define the role of  T cell subpopulations (CD4, 
CD8 and V~3 specific) in tumor reactivity in vitro and in 
vivo. 
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